Featured Content

Launching Biosimilars in Emerging Markets

In the lead up to the forthcoming “Biosimilars Commercialisation Summit” happening in May 2019, Pharma IQ  had the opportunity to interview industry experts:

  • Jose Carlos Ferreyra, President at Mexican Pharmaceutical Institute 
  • Fabiola Santillan, Country Manager at TTY Biopharm
  • Pankaj Chaudhari, Manager - Global Regulatory Affairs (Biosimilars) at IQVIA

They shared their thoughts on the key factors to take into account when launching in the South Asian and Latin American regions.

Download the full interviews to get insights on how to win in these markets.

Biosimilars Investment Trends 2019

We asked commercialisation experts from the biosimilars industry about how they are investing in their development, and market access strategy.

Download this piece to learn about:

  • The reasons why companies aren't currently outsourcing 
  • The biggest factors in choosing a new solution provider
  • The biggest challenges in biosimilar commercialisation currently

Switching between Biologics and Biosimilars

Ahead of the Biosimilars Commercialisation Summit Pharma IQ sat down and spoke with Kalveer Flora, Specialist Pharmacist Rheumatology and Biosimilars, London North West Healthcare NHS Trust to talk about the adoption of biosimilars in the market.

Download this piece to gain insight into:

  • The importance of offering patients guidance when switching between biologics and biosimilars 
  • What concerns inhibit prescribers switching patients to biosimilars
  • How the UK market compares to the rest of the world on stakeholder confidence and acceptance of biosimilars 

Cost, Confidence and Competition: Understanding the Current and Future Biosimilars Market

Ahead of the Biosimilars Commercialisation Summit, Pharma IQ have analysed the influence of cost, confidence and completion in the globalisation of biosimilars, with the intent to understand the future of the biosimilars market. With insights from Stephen Murby.

Download this piece to learn more about:

  • The influence of cost, confidence and completion in the globalisation of biosimilars
  • The Japan and China biosimilars market
  • The Europe and the US biosimilars market

Top 10 Challenges: Producing commercial cell and gene products

The international regenerative medicines market – which includes the likes of cell therapies, gene/gene-modified cell therapy and tissue engineering – is set to climb to around $67 billion by 2020.  Alongside, discovering therapies that will treat cancer and orphan diseases, many in the industry are hungry to land grab market share and produce the next blockbuster product. 

Pharma IQ spoke to Dieter Hauwaerts, VP Operations, Celyadand other industry experts  about the top challenges in the Manufacturing Commercialised Cell & Gene Therapies sector.

Download this piece to learn more about:

  • Product quality awareness and how functionality tests make manufacturing in a QbD space difficult
  • How Downstream processing times that are elongated can have a direct impact on cell quality as the scale is upped
  • How stable funding is hard to access with the lengthy R&D timelines and changing regulatory parameters that surround cell and gene therapies

Pharmatching Portrays Biosimilars

Due to the complex nature of biosimilars, pharma manufacturers need to rely, partly or to a large extent, on external capacities and expertise. The more classically generic the company’s background, the more this holds true. In this issue of Pharmatching Portrays, we showcase some of the Specialist Providers that have stepped in to meet this demand.

Pharma IQ spoke to Dr. Gabriele Dallmann, CEO of Pharmatching.com about biosimilar and the guidelines, players and providers in the sector.

Download this piece to learn more about:

  • The challenges of biosimilar monoclonal antibodies
  • The players and their responsibilities within the sector
  • Regulatory guidance at a glance

5 thoughts for physicians switching patients to biosimilars

In response to the recent bioboom, physicians may consider switching patients to a biosimilar for a more affordable alternative. However, this is a decision that shouldn’t be made in haste and has a few crucial points to be considered.

Pharma IQ spoke to The European Trade Association for biopharmaceutical companies (EBE), European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Download this piece to learn more about the guidance they provided on the key aspects that should frame the decision making process when contemplating a switch to biosimilars.

Cell and Gene Theraphy Infographic

Over the last 12 months, the cell and gene therapy manufacturing sphere has matured vastly with more companies advancing to commercial products, especially with allogenic therapies. Now that the theory behind the therapy is catching up with the technology, the two can come together to progress towards producing commercial products.

Pharma IQ created a report on the cell and gene manufacturing activity that is occurring across Europe regarding the road to commercializing these therapies. Download this piece to learn more about what clinical trials happening across Europe and what stage/ focus they are in. 

Cell & Gene Manufacturing Process Efficiencies: Best Practice Guide

The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.

Pharma IQ spoke with Elena Meurer, Head of Pharmaceutical and Technical Development at apceth GmbH & Co.KG about the progress required behind this market in regards to process excellence Download this piece to learn more about:

  • The level of process efficiency behind today’s cell and gene therapies
  • The two major routes towards improvement Elena Meurer sees for the future
  • The greatest challenges for the market

Supplying for the Biologics Boom

The rising use of biosimilars  is expected to result in the near doubling of the size of pharma cold chain logistics business over the next three years. Pharma IQ spoke with Javier Gomez-Contreras Supply Chain BGx LATAM of GSK about the prospects for vaccine distribution as the industry serves the rise in demand.

Download this piece to learn more about:

  • How cold chain processes have to be adapted when transporting vaccines
  •  What the biggest challenges for the future of vaccine distribution are
  • Which new technologies can support how these vaccines are transported